Ruxolitinib with radiation and chemo for newly diagnosed glioblastoma
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This trial tests whether adding the drug ruxolitinib to standard radiation and chemotherapy (temozolomide) helps people with a newly diagnosed brain tumor called glioblastoma. It aims to see if the combination keeps the tumor from growing longer than the standard treatment alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old and have been diagnosed with glioblastoma, a type of brain tumor, that has not been treated yet.
- You are able to care for yourself with only occasional help from others (a score of 70% or higher on a standard function scale).
- Your blood counts and liver and kidney function are within acceptable levels, as tested within 2 weeks before starting the study.
- You can swallow pills.
- You have no other active cancer, except for certain early-stage or fully cured cancers, and you have been cancer-free for at least 3 years if you had any other cancer before.
- If you are able to become pregnant, you must agree to use effective birth control and have a negative pregnancy test.
- You are not taking warfarin (a blood thinner) and have not taken ruxolitinib before.
- You do not have uncontrolled HIV, active tuberculosis, or active hepatitis B or C infections.
- You have not had certain live vaccines within 6 weeks before the study starts.
- You do not have significant heart problems, such as uncontrolled irregular heartbeat or heart failure.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests whether liposomal curcumin, added to standard radiation plus temozolomide, can improve treatment outcomes in newly diagnosed high-grade gliomas. It focuses on safety and how well the treatment can be given with the usual therapy plan.
This study tests a new medicine (MT-125) combined with standard radiation and chemotherapy for people with newly diagnosed glioblastoma that has a specific gene change (MGMT methylated). The goal is to see if it is safe and tolerable, and to look for early signs it might help.
This trial tests whether adding the study drug azeliragon to standard radiation and chemotherapy can help people with newly diagnosed glioblastoma. The study will also look at how the tumor responds to the added drug.
This trial compares two standard treatments for newly diagnosed glioblastoma (a serious brain cancer) in older and frail patients: chemo plus radiation versus chemo alone. It may help determine which approach works best and is safest for people in your age and health group.
This trial tests giving a chemotherapy drug called temozolomide before radiation therapy to people with a newly diagnosed high-grade brain tumor. The goal is to see if this approach can help control the tumor better.
This trial studies different treatment regimens for people with glioblastoma that is either newly diagnosed or has come back. It aims to find which treatment approach works best for controlling the tumor and improving outcomes.
Hear when a new Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.